Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0H3ZG
|
|||
Drug Name |
Six-membered heterocyclic benzamide derivative 2
|
|||
Synonyms |
PMID28270021-Compound-WO2015143654Example41
Click to Show/Hide
|
|||
Indication | Chronic pain [ICD-11: MG30; ICD-10: R52.1, R52.2; ICD-9: 338.2, 780] | Patented | [1] | |
Neuropathic pain [ICD-11: 8E43.0] | Patented | [1] | ||
Pruritus [ICD-11: EC90; ICD-10: L29, L29.9] | Patented | [1] | ||
Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Patented | [1] | ||
Thymic cancer [ICD-11: 2C27; ICD-10: C37] | Patented | [1] | ||
Company |
MERCK SHARP & DOHME CORP
|
|||
Structure |
Download2D MOL |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1] |
Target's Patent Info | Tropomyosin-related kinase A (TrkA) | Target's Patent Info | [1] | |
KEGG Pathway | MAPK signaling pathway | |||
Endocytosis | ||||
Apoptosis | ||||
Neurotrophin signaling pathway | ||||
Inflammatory mediator regulation of TRP channels | ||||
Pathways in cancer | ||||
Transcriptional misregulation in cancer | ||||
Thyroid cancer | ||||
Central carbon metabolism in cancer | ||||
NetPath Pathway | IL2 Signaling Pathway | |||
Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | |||
Reactome | Frs2-mediated activation | |||
ARMS-mediated activation | ||||
NGF-independant TRKA activation | ||||
PI3K/AKT activation | ||||
WikiPathways | MAPK Signaling Pathway | |||
BDNF signaling pathway | ||||
Integrated Pancreatic Cancer Pathway | ||||
NGF signalling via TRKA from the plasma membrane |
References | Top | |||
---|---|---|---|---|
REF 1 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.